ISRGHealthcare · Medical Instruments & SuppliesThe 33 Wall Street analysts covering Intuitive Surgical, Inc. hold a median 12-month price target of $483 — +28.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 77 of 100 as at 1 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Intuitive Surgical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (96): Analysts have, on balance, been raising their forecasts.
Momentum (27): The shares have been drifting down relative to others.
Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.
The rank is the raw material. Whether the rules would actually own Intuitive Surgical, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on ISRG, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +28.7% from it.
Of the 20 most recent actions, 0 moved their price target up and 10 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 July 2026 | HSBC | Downgrade | Hold | $931 |
| 28 July 2026 | UBS | Assumes | Buy | $550 → $500 |
| 17 July 2026 | Baird | Maintains | Outperform | $525 → $500 |
| 17 July 2026 | Baird | Maintains | Outperform | — |
| 17 July 2026 | Bernstein | Maintains | Outperform | $750 → $685 |
| 17 July 2026 | Bernstein | Maintains | Outperform | — |
| 17 July 2026 | BTIG | Maintains | Buy | $512 → $469 |
| 17 July 2026 | BTIG | Maintains | Buy | — |
| 17 July 2026 | Citigroup | Maintains | Buy | — |
| 17 July 2026 | Citigroup | Maintains | Buy | $590 → $500 |
| 17 July 2026 | Evercore ISI Group | Maintains | In-Line | — |
| 17 July 2026 | Evercore ISI Group | Maintains | In-Line | $430 → $375 |
| 17 July 2026 | JP Morgan | Maintains | Overweight | — |
| 17 July 2026 | JP Morgan | Maintains | Overweight | $550 → $450 |
| 17 July 2026 | Leerink Partners | Maintains | Outperform | $573 → $454 |
| 17 July 2026 | Leerink Partners | Maintains | Outperform | — |
| 17 July 2026 | Mizuho | Maintains | Neutral | — |
| 17 July 2026 | Mizuho | Maintains | Neutral | $500 → $400 |
| 17 July 2026 | Piper Sandler | Reiterates | Overweight | $580 → $470 |
| 17 July 2026 | Piper Sandler | Reiterates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 20% of US stocks
Cheaper than 13% of US stocks
Cheaper than 15% of US stocks
Cheaper than 10% of US stocks
Higher than 70% of US stocks
Higher than 65% of US stocks
Higher than 81% of US stocks
Higher than 90% of US stocks
Higher than 88% of US stocks
Higher than 79% of US stocks
Higher than 93% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ISRG appears on the weeks it earns a place.
Intuitive Surgical (ISRG) has recently garnered significant attention from users of Zacks.com, prompting analysis of the stock's future prospects.
Why it matters — The heightened investor interest in ISRG suggests the stock is under increased scrutiny, making it important for current holders to understand what may be driving the attention.
Zacks reports that Intuitive Surgical is expanding robotic surgery beyond urology, with general surgery and newer specialties gaining traction and providing avenues for long-term procedure growth.
Why it matters — ISRG watchers would care because the expansion into specialties beyond urology could broaden the company's addressable market and drive future procedure volume growth.
Intuitive Surgical's Q2 earnings call highlighted durable platform demand and raised margin guidance, while also noting softer U.S. procedure growth and caution around deferred care.
Why it matters — ISRG watchers would care because the call presents a mixed outlook of strong platform demand against a more cautious U.S. procedural environment.
Intuitive Surgical's stock fell 37% to around $355, with a Wall Street professional setting a price target of $685, while the average analyst target stands at $484.40.
Why it matters — The wide gap between the current share price, the average analyst target, and one professional's bullish call indicates significant divergence in market expectations for ISRG's recovery.
The Silvant Large Cap Growth SMA returned +14.61% (gross)/+13.79% (net) for Q2 2026 versus the Russell 1000 Growth Index's +16.74%, and Intuitive Surgical was listed among the largest stock detractors from relative performance.
Why it matters — ISRG investors should note that the stock underperformed relative to its benchmark during the quarter, according to this portfolio update.
The 33 Wall Street analysts covering Intuitive Surgical, Inc. have a median 12-month price target of $483, with estimates ranging from $324 to $685. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 33 analysts covering Intuitive Surgical, Inc., 23 rate it a Buy, 9 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Intuitive Surgical, Inc. 77 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Intuitive Surgical, Inc. ranks 77 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (96 of 100).
No one can know that. What the data says: the median 12-month target from 33 analysts implies +28.7% from the last close, and Ticker Nerd's factor model ranks Intuitive Surgical, Inc. 77 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Intuitive Surgical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ISRG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $324 to $685 over the next 12 months.
Intuitive Surgical, Inc. returned -22.3% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Intuitive Surgical, Inc. is a medical technology company that develops, manufactures, and markets robotic-assisted systems designed to support minimally invasive care in hospitals and healthcare facilities worldwide.
The most recent item we track (Zacks Investment Research, 31 July 2026): "Intuitive Surgical, Inc. (ISRG) is Attracting Investor Attention: Here is What You Should Know". Intuitive Surgical (ISRG) has recently garnered significant attention from users of Zacks.com, prompting analysis of the stock's future prospects.
Intuitive Surgical, Inc. is a medical technology company that develops, manufactures, and markets robotic-assisted systems designed to support minimally invasive care in hospitals and healthcare facilities worldwide. Its primary platforms include the da Vinci Surgical System, which enables surgeons to perform complex procedures through small incisions with enhanced precision, visualization, and control, and the Ion endoluminal system, which focuses on minimally invasive lung biopsies and diagnostic procedures. Intuitive Surgical provides a comprehensive ecosystem around these systems, including surgical instruments, disposable accessories, vision and imaging technologies, training, and technical support services. The company works closely with surgeons and healthcare providers across specialties such as urology, gynecology, general surgery, and thoracic care, aiming to broaden access to minimally invasive treatment options. Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California.
CEO Mr. David J. Rosa · 17,021 employees · United States · https://www.intuitive.com